SCHEMBL222907

SCHEMBL222907

O=COc1cccc2nc3ccccc3cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
GAA P10253 3/20 0.50
KMT2A Q03164 3/20 0.50
GLA P06280 2/20 0.50
HPGD P15428 2/20 0.50
RAB9A P51151 2/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
PTBP1 P26599 1/20 0.50
RCE1 Q9Y256 1/20 0.50
MAPT P10636 3/20 0.45
ACHE P22303 1/20 0.45
NQO2 P16083 3/20 0.38
MEN1 O00255 1/20 0.38
HTT P42858 2/20 0.37
ESR1 P03372 2/20 0.37
ESR2 Q92731 2/20 0.37
TLR8 Q9NR97 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL7769205 0.98 ALDH1A1 (0.49) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL5192732 0.80 KMT2A (0.58) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL8740692 0.79 ALDH1A1 (0.44) ALDH1A1KMT2AGLAHPGDRAB9A
SCHEMBL3482649 0.79 ALDH1A1 (0.43) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL214710 0.79 ALDH1A1 (0.42) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL240664 0.77 NQO2 (0.57) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL28934937 0.77 ALDH1A1 (0.41) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL28934949 0.77 ALDH1A1 (0.41) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL28934913 0.77 ALDH1A1 (0.41) ALDH1A1GAAKMT2AGLAHPGD
SCHEMBL28934953 0.77 ALDH1A1 (0.41) ALDH1A1GAAKMT2AGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190175566-A1 ANTI-TUMOR COCKTAIL COMPRISING AN ANTI-TUMOR AGENT SELECTIVE FOR TUMOR ACIDITY, AN ANTIOXIDANT, AND A P-GLYCOPROTEIN INHIBITOR ARION TECNOLOGIA BRASIL - GESTÃO DE ATIVOS S/A (BR) 2019-06-13 US claimed
EP-1301485-B1 NOVEL HETEROARYL DERIVATIVES AND THE USE THEREOF AS PHARMACEUTICALS ZENTARIS GMBH (DE) 2007-06-27 EP claimed
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors ZENTARIS GMBH (DE) 2005-01-13 US claimed
US-6706722-B2 IN PARTICULAR FOR TREATING TUMORS. ZENTARIS AG (DE) 2004-03-16 US claimed
US-20020132821-A1 Novel heteroaryl derivatives and their use as medicaments ZENTARIS GMBH (DE) 2002-09-19 US claimed
EP-0725651-B1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1999-08-11 EP claimed
US-5830867-A Hemoregulatory peptides for stimulating the myelopoietic system SMITHKLINE BEECHAM CORPORATION (US) 1998-11-03 US claimed
US-5652219-A Hemoregulatory peptides SMITHKLINE BEECHAM CORPORATION (US) 1997-07-29 US claimed
EP-0701446-A4 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1997-04-23 EP claimed
EP-0621788-A4 HEMOREGULATORY PEPTIDES. SMITHKLINE BEECHAM CORP (US) 1997-03-05 EP claimed
EP-0725651-A4 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORP (US) 1997-03-05 EP claimed
EP-0725651-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-14 EP claimed
EP-0701446-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1996-03-20 EP claimed
WO-1995011693-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-04 WO claimed
WO-1994027627-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-12-08 WO claimed
WO-1994028420-A1 METHOD OF DETECTION OF BACTERIA RHONE POULENC DIAGNOSTICS LTD (GB) 1994-12-08 WO claimed
EP-0621788-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1994-11-02 EP claimed
WO-1993013789-A1 HEMOREGULATORY PEPTIDES SMITHKLINE BEECHAM CORPORATION (US) 1993-07-22 WO claimed
WO-2025070135-A1 HEXAVALENT-CHROMIUM-REDUCING PHOTOCATALYST COMPOSITION AND METHOD FOR REDUCING HEXAVALENT CHROMIUM ユシロ化学工業株式会社 2025-04-03 WO disclosed
US-4451474-A T-Butyl-phenoxy-alkylene esters of benzoic and nicotinic acids, compositions containing same and their antihistaminic method of use Berger, Frank M. (US) 1984-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009809-A1 Aryl- and heteroaryl-substituted piperazinylcarbonyl acridines and their homologs, e.g., (1,3-dihydroxyacridin-9-yl)-[4-(6-methyl pyridin-2-yl )piperazin-1-yl]methanone,are suitable for treating benign and malignant tumors PKD1, MDH2, MSH2 ALDH1A1 23/4885GAA 3585/4885KMT2A 1945/4885
US-20190175566-A1 ANTI-TUMOR COCKTAIL COMPRISING AN ANTI-TUMOR AGENT SELECTIVE FOR TUMOR ACIDITY, AN ANTIOXIDANT, AND A P-GLYCOPROTEIN INHIBITOR ABCG2, SDHA, ABCB1 ALDH1A1 444/4885GAA 51/4885KMT2A 3489/4885
US-20020132821-A1 Novel heteroaryl derivatives and their use as medicaments ABCB1, ABCB11, FANCD2 ALDH1A1 173/4885GAA 483/4885KMT2A 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.